小児・若年者の難治性または再発性ホジキンリンパ腫に対する抗体薬物複合体ブレンツキシマブとゲムシタビン併用療法:多施設共同単群第Ⅰ/Ⅱ相試験AHOD1221【Lancet Oncol】

42例中28例(67%)で奏効し、治療関連死は認められなかった。

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a Children’s Oncology Group, multicentre single-arm, phase 1–2 trial

Lancet Oncology 2018年8月16日オンライン版

Patients with primary refractory Hodgkin’s lymphoma or early relapse have a poor prognosis. Although many salvage regimens have been developed, there is no standard of care. Brentuximab vedotin and gemcitabine have been shown to be active in patients with relapsed or refractory Hodgkin’s lymphoma when used as monotherapy, and each has been successfully used in combination with other agents. Preclinical data suggest that brentuximab vedotin can sensitise lymphoma cells to gemcitabine, supporting the use of the combination. We aimed to define the safety and efficacy of brentuximab vedotin with gemcitabine in children and young adults with primary refractory Hodgkin’s lymphoma or early relapse.

 

コメント

Leave a comment

Your email address will not be published.


*